A new drug, daraxonrasib, has shown unprecedented results in treating metastatic pancreatic cancer, doubling patient survival rates in a Phase III trial. This breakthrough targets the previously 'undruggable' RAS oncogene, offering new hope for a disease with historically poor outcomes.
Metastatic triple-negative breast cancer (mTNBC) is aggressive and hard to treat. A new Trop-2 ADC drug, now covered by Taiwan's National Health Insurance, precisely targets cancer cells, improving outcomes and reducing side effects for patients like Ms. Chen, offering a new lease on life.
A 41-year-old mother, "Xiao Ya," successfully battled metastatic breast cancer whose cells changed type three times, from HER2-positive to triple-negative, and finally to HER2-low-positive. New precision drugs, including ADC medications, have helped her overcome the evolving tumor. However, Taiwan's National Health Insurance does not yet cover these treatments for advanced and metastatic HER2-low-positive patients, raising concerns about unequal access to care.
Labour MP Ashley Dalton, who has terminal breast cancer, has urged MPs not to revive the assisted dying bill. She argued the bill was flawed and could have unintended consequences for vulnerable people, despite her own diagnosis.
